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Abstract
Purpose The effect of adding contact force (CF) sensing to 56-hole tip irrigation in ventricular arrhythmia (VA) ablation has not
been previously studied. We aimed to compare outcomes with and without CF sensing in VA ablation using a 56-hole radiofre-
quency (RF) catheter.
Methods A total of 164 patients who underwent first-time VA ablation using Thermocool SmartTouch Surround Flow (TC-
STSF) catheter (Biosense-Webster, Diamond Bar, CA, USA) were propensity-matched in a 1:1 fashion to 164 patients who had
first-time ablation using Thermocool Surround Flow (TC-SF) catheter. Patients were matched for age, gender, cardiac aetiology,
ejection fraction and approach. Acute success, complications and long-term follow-up were compared.
Results There was no difference between procedures utilising either TC-SF or TC-STSF in acute success (TC-SF: 134/164
(82%), TC-STSF: 141/164 (86%), p = 0.3), complications (TC-SF: 11/164 (6.7%), TC-STSF: 11/164 (6.7%), p = 1.0) or VA-free
survival (TC-SF: mean arrhythmia-free survival time = 5.9 years, 95% CI = 5.4–6.4, TC-STSF: mean = 3.2 years, 95% CI = 3–
3.5, log-rank p = 0.74). Fluoroscopy time was longer in normal hearts with TC-SF (19 min, IQR: 14–30) than TC-STSF (14 min,
IQR: 8–25; p = 0.04).
Conclusion Both TC-SF and TC-STSF catheters are safe and effective in treating VAs. The use of CF sensing catheters did not
improve safety or acute and long-term outcomes, but reduced fluoroscopy time in normal heart VA.
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1 Introduction
Catheter ablation is an important treatment for ventricular ar-
rhythmias (VA) [1], but long-term outcomes remain subopti-
mal. Measuring the contact force (CF) between the radiofre-
quency (RF) ablation catheter and myocardium aims to im-
prove mapping accuracy, energy delivery and procedure safe-
ty, by optimising catheter-tissue contact. In comparison to the
large volume of data available on measuring CF in AF
ablation, much less work has focused on its real-world useful-
ness in VA.
This study compares acute success, complication rate and
long-term arrhythmia-free survival in catheter ablation proce-
dures for VA using the 56-hole RF ablation Thermocool
Surround Flow (TC-SF) catheter versus the Thermocool
SmartTouch Surround Flow (TC-STSF) catheter (both
Biosense Webster, Diamond Bar, CA, USA). The latter com-
bines the ability to monitor the magnitude and direction of
catheter-tissue contact with entire tip irrigation.
2 Methods
2.1 Patient population
Procedure- and outcome-related data were collected for the
164 patients undergoing first-time ablation for VA using TC-
STSF catheter between 2016 and 2018 at St George’s
University Hospital, London, UK (91 with structurally normal
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heart, 38 with ischemic cardiomyopathy (ICM) and 35 with
non-ischemic cardiomyopathy (NICM)). From a database of
264 first-time VA ablation procedures performed in the same
institution using TC- SF catheter, one procedure was
propensity-matched against each TC-STSF procedure
(Fig. 1). The study was approved by the local institutional
research ethics committee.
There were 209 procedures for ventricular ectopy (VE) and
119 for ventricular tachycardia (VT). The data comprised
baseline patient demographics, left ventricular ejection frac-
tion (LVEF), presence and indication for intracardiac devices,
number of prior ablations and underlying cardiac aetiology.
All patients underwent a transthoracic echocardiogram (TTE)
or cardiac magnetic resonance imaging (cMRI), or both, pre-
procedurally. Coronary angiography was performed in all
cases of structural heart disease and was discretional in the
case of normal heart VAs.
The indication for VA ablation was categorised as symp-
tomatic despite medical therapy, presumed VA-induced car-
diomyopathy unresponsive to medical therapy, recurrent im-
plantable cardioverter defibrillator (ICD) shocks or VT storm.
Antiarrhythmic drug therapy was discontinued for 5 half-
lives, except for patients presenting with VT storm or those
on Amiodarone. Scar-dependent VT ablation was performed
under general anaesthesia or conscious sedation. Sub-xiphoid
epicardial approach was undertaken at the discretion of the
operator and was based on clinical aetiology, pre-procedural
imaging or prior procedural mapping.
2.2 Definitions
VA was defined as either VT or VE. Normal heart VA was
defined as the absence of structural abnormality on TTE or
cMRI. Acute procedural success was defined as non-
inducibility of all VT(s) and the complete elimination of
scar-related abnormal electrograms in VT cases and as >
80% reduction in clinical VE frequency despite isoprenaline
challenge, during a 30-min wait period in VE cases. VA re-
currence was defined as sustained monomorphic VT (> 30 s)
or VT requiring ICD therapy (anti-tachycardia pacing or
shock) for patients undergoing VT ablation and as < 80% re-
duction of the burden of clinical ectopy on 24-h Holter mon-
itoring in patients undergoing VE ablation.
2.3 Ablation strategy
Dual left ventricular (LV) access was employed in scar-
dependent VT cases, using both the trans-septal and the retro-
grade aortic approaches. Anticoagulation during LV proce-
dures was maintained with unfractionated Heparin and titrated
to achieve an activated clotting time of 300–400 s.
Patients underwent electroanatomical mapping during VA
or in sinus rhythm with either the CARTO 3 (Biosense-
Webster, Diamond Bar, CA, USA) or the Ensite Velocity/
Precision System (St. Jude Medical, St Paul, MN, USA) and
TC-SF or the CARTO 3 system and TC-STSF (Biosense-
Webster, Inc.), with TC-STSF largely supplanting TC-SF in
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Fig. 1 Flowchart for the study
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2016. Both catheters have a 3.5 mm tip with 56 pores in the
distal electrode through which normal saline was infused at a
rate of 2 ml/min during mapping. While using the TC-STSF
catheter, the average and maximum CF between the catheter
tip and the myocardium were measured and expressed in
grams (g), aiming for CF of 10–40 g. Mapping was supple-
mented by multi-electrode mapping catheters, which were
more commonly used in the latter years of the study.
Voltage mapping was performed during sinus rhythm or
right ventricular (RV) pacing at the outset. Programmed stim-
ulation was performed with up to 3 extrastimuli at 2 cycle
lengths. Ablation was performed in the power control mode,
with temperature cut-off of 40 °C, maximum power of 40 W
(rarely up to 50W on the interventricular septum), flow rate of
17 ml/min, duration of RF application of 60 s at each point,
with lower energy and shorter duration at aortic sinus of
Valsalva and para-Hisian locations. Ablation was terminated
immediately if there was an impedance rise or an audible
steam pop.
For VT cases, ablation of all clinical VTs was attempted.
Abnormal scar-related electrograms were targeted with focal
ablation in scar with endocardial voltage < 1.5 mV, aiming at
the elimination of near-field electrograms, impedance drop of
10 Ω and loss of capture with moderate output pacing [2].
For VE cases, ablation was performed at the earliest site of
local activation and/or the site of best pacemap (> 90%) match
to the clinical VE.
2.4 Follow-up
All major intra- and post-procedural complications were re-
corded up to 30 days. Antithrombotic therapy was recom-
mended for 1–3 months after LV endocardial procedures with
either direct oral anticoagulants or warfarin with a goal inter-
national normalised ratio of 2–3. Long-term follow-up data
were obtained from outpatient clinic, ambulatory electrocar-
diographic recordings and device interrogation reports.
Follow-up for at least 1 year was available for 317 of 328
(96.6%) procedures, with a median follow-up duration of
5.4 years (interquartile range (IQR) = 4.1–6.3 years) for TC-
SF and 2.3 years (IQR = 1.6–3.4 years) for TC-STSF.
2.5 Statistical analysis
A propensity score was calculated for all eligible patients un-
dergoing first-time RF ablation for VAs through binary logis-
tic regression with ablation catheter (TC-STSF or TC-SF) as
the binary outcome and baseline variables were used as co-
variates for estimating the propensity score. Propensity
matching was performed in a 1:1 fashion using the nearest
neighbour approach with a two-decimal calliper for age, sex,
aetiology, LVEF and approach (endocardial or epicardial). If
no match could be found, then the TC-STSF subject was
removed from the analysis. Univariate analyses of dichoto-
mous, categorical and continuous variables were performed
to determine similarities or differences between TC-SF and
TC-STSF in normal heart, ICM and NICM groups.
Categorical data were compared using the Chi-square test.
The distribution of continuous variables was assessed for nor-
mality with Shapiro-Wilk test. Student’s t test was used to
compare normally distributed data and Mann-Whitney U test
to compare non-parametric data between TC-SF and TC-
STSF groups. Kaplan-Meier time event analysis was used to
asses VA recurrence in each group, comparing TC-SF vs TC-
STSF and significance determined by the log-rank test.
Similarly, ICD shock recurrence and overall survival were
compared in patients with ICM and NICM. Receiver operat-
ing characteristic (ROC) analysis was performed to find the
average CF correlating with acute procedure success.
Statistical analysis was performed using SPSS statistical soft-
ware, version 26 (IBM Corp., Chicago, IL, USA).
3 Results
3.1 Patient details
Baseline characteristics are presented in Table 1. Procedures
using either TC-SF or TC-STSF were well matched in pa-
tients’ gender distribution, age, distribution of cardiac
aetiology and LVEF. There was no difference in the propor-
tion of patients with implanted cardiac devices, indication for
device implantation or indication for ablation.
Pre-procedure cMRI was performed in 57/164 (35%) pa-
tients in the TC-SF group and 43/164 (26%) patients in the
TC-STSF group (p = 0.09), with no difference in demographic
characteristics between the patients in whom cMRI was per-
formed in both groups. There was no difference between the
two groups regarding the size of scar in patients with ICM, as
measured by late gadolinium enhancement, TC-SF: median =
6 segments, IQR = 4–7; TC-STSF: median = 8 segments,
IQR = 5–9, p = 0.12.
3.2 Procedure characteristics
Procedure characteristics are shown in Table 2. There was no
difference in the type of arrhythmia targeted, the approach
used, procedure duration, duration of RF energy application
or maximum power applied.
In patients presenting with VT, there was no difference in
the number of VTs induced between both study groups (TC-
SF: median = 1, IQR = 1–2; TC-STSF: median = 1, IQR = 1–
2; p = 0.7). The clinical VT as well as any induced sustained
VT was targeted for ablation.
With all etiologies combined, fluoroscopy time was shorter
with TC-STSF (median: 16 min, IQR: 9–27) than TC-SF
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(median: 21 min, IQR: 13–31), p = 0.008. However, this dif-
ference was only significant in the normal heart group (TC-
SF: median = 19 min, IQR = 14–30, TC-STSF: median =
14 min, IQR = 8–25, p = 0.04) but not in ICM or NICM
groups (Table 2).
When examining patients undergoing VE and VT ablation
separately (Table 3), fluoroscopy time was shorter with the use
of TC-STSF in VE ablation (TC-SF: median = 23 min, IQR =
15–41, TC-STSF: median = 17 min, IQR = 8–25, p = 0.009).
Table 1 Baseline characteristics
Normal heart (182) ICM (76) NICM (70)
TC-SF (91) TC-STSF (91) P TC-SF (38) TC-STSF (38) P TC-SF (35) TC-STSF (35) P
Male gender 40 (44) 41 (45) 0.9a 32 (84) 34 (90) 0.5a 27 (77) 25 (71) 0.09a
Age 50 ± 15 49 ± 16 0.7b 67.8 ± 8 68 ± 10 0.89b 57 ± 15 58 ± 15 0.7b
LVEF (%) 59 ± 3 59 ± 3 0.7b 39 ± 12 37 ± 12 0.4b 44 ± 13 42 ± 12 0.4b
Device
ICD 1.0a 17(45) 17 (45) 1.0a 12 (34) 10 (29) 0.4a
CRT-D 9 (24) 10 (26) 6 (17) 11 (31)
Pacemaker 0 1 1 (3) 1 (3)
Device indication
1ry prevention 13 11 0.45a 8 9 0.9a
2ry prevention 13 16 10 12
Ablation indication
Symptomatic 82 86 0.4a 13 12 0.5a 9 11 0.6a
ICD shocks 16 19 11 14
VT storm 9 7 6 3
Reduced LVEF 9 5 9 7
Values are presented as count (percentage) or mean ± standard deviation
1ry primary, 2ry secondary, CRT-D cardiac resynchronisation therapy-defibrillator, CRT-P cardiac resynchronisation therapy-pacing only, ICD implant-
able cardioverter defibrillator, ICM ischemic cardiomyopathy, LVEF left ventricular ejection fraction, NICM non-ischemic cardiomyopathy, TC-SF
Thermocool Surround Flow catheter, TC-STSF Thermocool SmartTouch Surround Flow catheter, VT ventricular tachycardia
a Chi-square test
b Student’s t test
Table 2 Procedure details
Normal heart (182) ICM (76) NICM (70)
TC-SF (91) TC-STSF (91) P TC-SF (38) TC-STSF (38) P TC-SF (35) TC-STSF (35) P
Type of VA
VE 75 80 0.3a 10 10 1.0a 18 16 0.6a
VT 16 11 28 28 17 19
Approach
Endocardial 91 91 38 37 1.0a 34 34 1.0a
Epicardial-endocardial 0 1 1 1
Procedure duration (min) 140 (120–170) 162 (135–186) 0.07b 245 (198–318) 210 (190–279) 0.3b 231 (162–253) 210 (139–301) 0.8b
Fluoroscopy time (min) 19 (14–30) 14 (8–25) 0.04b 33 (17–47) 27 (17–65) 0.2b 35 (15–47) 30 (20–39) 0.3b
RF time (min) 12 (7–23) 12 (6–23) 0.2b 27 (17–50) 27 (13–43) 0.98b 21 (12–36) 22 (19–32) 0.2b
Maximum power (W) 30 (27–35) 30 (25–30) 0.8b 35 (30–35) 30 (30–40) 0.7b 30 (30–35) 35 (30–40) 0.3b
Values are presented as count (percentage) or median (interquartile range)
ICM ischemic cardiomyopathy,minminute,NICM non-ischemic cardiomyopathy,RF radiofrequency, TC-SF Thermocool Surround Flow catheter, TC-
STSF Thermocool SmartTouch Surround Flow catheter, VA ventricular arrhythmia, VE ventricular ectopics, VT ventricular tachycardia, W Watts
a Chi-square test
bMann-Whitney test
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There were no other differences in procedure duration, dura-
tion of RF energy application or maximum power applied.
In the TC-STSF group, the median for average CF during
RF delivery was 13 g, IQR = 10–19 and the median for max-
imum CF = 64 g, IQR = 42–80. The average CF in patients
undergoing VA ablation for non-outflow LV sites was higher
with the trans-mitral approach (median = 19 g, IQR = 12–25)
than with the trans-aortic approach (median = 14 g, IQR = 9–
18, p = 0.02). Likewise, the trans-mitral approach was associ-
ated with higher maximum CF (median = 90 g, IQR = 69–
103) than the trans-aortic approach (median = 69, IQR = 41–
88, p = 0.03).
An average CF greater than 5 g during RF delivery could
not be reached in 4 of 164 patients (2.4%); 2 cases involved
ablation in dilated RV outflow tracts, one involved the anterior
mitral annulus and one involved basal LV ablation for LV
summit VE.
3.3 Acute success and 30-day complications
There was no difference between procedures utilising either
TC-SF or TC-STSF in acute success (TC-SF: 134/164 (82%),
TC-STSF: 141/164 (86%), p = 0.3). No difference in acute
success was observed between the two catheters when VE
and VT ablations were analysed separately (Table 3) or in
normal hearts, ICM or NICM (Table 4).
Likewise, there was no difference in complications be-
tween TC-SF (11 of 164, 6.7%) and TC-STSF (11 of 164,
6.7%, p = 1.0) catheter groups, and this applied to VE and
VT ablations (Table 3) as well as normal hearts, ICM and
NICM (Table 4). There was no association betweenmaximum
CF and incidence of tamponade, but the numbers were too
small to demonstrate a difference. There were two deaths
within 30 days of the procedure; both patients had advanced
heart failure with severely depressed LVEF (< 20%).
Tamponade requiring drainage occurred in 9 (2.7%) proce-
dures, 8 of which resolved with pericardiocentesis and one
associated with TC-STSF use required surgical repair. Of
the four tamponades occurring with TC-SF, two occurredwith
ablation in the right ventricular outflow tract (RVOT), one
with ablation in the right coronary cusp and one occurred
1.5 months later due to pericarditis following an epicardial
ablation. Of the five tamponades occurring with TC-STSF,
two occurred with ablation in the left ventricle, one with ab-
lation in the aorto-mitral continuity, one with ablation in the
RVOT and one with ablation in the RV free wall.
One patient sustained acute left main coronary injury suc-
cessfully stented emergently, due to manipulation of TC-
STSF in the aortic root to target a papillary muscle VE, one
case of complete heart block occurred, and one patient suf-
fered a minor stroke. No other thromboembolic events were
observed.
Table 3 Comparison between the two catheters based on type of ventricular arrhythmia
Ventricular ectopy Ventricular tachycardia
TC-SF (103) TC-STSF (106) P TC-SF (61) TC-STSF (58) P
Procedure duration (min) 165 (140–253) 168 (133–208) 0.6a 199 (146–248) 210 (176–292) 0.4a
Fluoroscopy time (min) 23 (15–41) 17 (8–25) 0.009a 24 (19–31) 28 (15–37) 0.8a
RF time (min) 14 (8–20) 13 (7–22) 0.3a 23 (12–30) 28 (19–45) 0.4a
Maximum power (W) 30 (30–35) 30 (27–30) 0.9a 35 (30–35) 35 (30–40) 0.9a
Acute success 85 (83) 95 (90) 0.14b 49 (80) 46 (79) 0.9b
30-day complications 6 (6) 4 (4) 0.5b 5 (8) 6 (10) 0.3b
Tamponade 4 2 0 3
Stroke 1 0
Heart block 0 1
Vascular 1 0 2 2
Death 1 1
Pulmonary embolism 1 0
Pneumonia 1 0
Pericarditis 0 1
Coronary dissection 0 1
Values are presented as median (interquartile range) or count (percentage)
Min minute, RF radiofrequency, TC-SF Thermocool Surround Flow catheter, TC-STSF Thermocool SmartTouch Surround Flow catheter, WWatts
aMann-Whitney test
b Chi-square test
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3.4 Long-term follow-up
When comparing TC-SF and TC-STSF catheter groups, there
was no difference in VA-free survival in the whole study
group (TC-SF: mean estimated VA-free survival time =
5.9 years, 95% CI = 5.4–6.4, TC-STSF: mean = 3.2 years,
95% CI = 3–3.5, log-rank p = 0.74, Fig. 2a), normal hearts
(TC-SF: mean estimated VA-free survival time = 6 years,
95% CI = 5.3–6.7, TC-STSF: mean = 3.6 years, 95% CI =
3.3–3.9, log-rank p = 0.13, Fig. 2b), ICM (TC-SF: mean esti-
mated VA-free survival time = 5.9 years, 95% CI = 4.9–7, TC-
STSF: mean = 2.4 years, 95%, CI = 2–2.9, log-rank p = 0.15,
Fig. 2c) or NICM (TC-SF: mean estimated VA-free survival
time = 5.6 years, 95% CI = 4.5–6.7, TC-STSF: mean =
1.8 years, 95% CI = 1.4–2.3, log-rank p = 0.11, Fig. 2d). No
difference in VA-free survival was observed between the two
catheters when comparing patients who underwent VE abla-
tion (TC-SF: mean estimated VA-free survival time =
5.9 years, 95% CI = 5.3–6.5, TC-STSF: mean = 3.4 years,
95% CI = 3.1–3.7, log-rank p = 0.35, Fig. 3a) or VT ablation
(TC-SF: mean estimated VA-free survival time = 6 years, 95%
CI = 5.2–6.9, TC-STSF: mean = 2.4 years, 95% CI = 2.0–2.8,
log-rank p = 0.053, Fig. 3b).
There was no difference in shock-free survival in either
patients with ICM (TC-SF: mean estimated shock-free surviv-
al time = 7.3 years, 95% CI = 6.5–8.1, TC-STSF: mean =
4.5 years, 95% CI = 4.1–4.8, log-rank p = 0.58, Fig. 4a) or
NICM (TC-SF: mean estimated shock-free survival time =
6.9 years, 95% CI = 5.8–8, TC-STSF: mean = 3 years, 95%
CI = 2.4–3.6, log-rank p = 0.09, Fig. 4b). Likewise, there was
no difference in overall survival in either patients with ICM
(TC-SF: mean estimated survival time = 7.2 years, 95% CI =
6.6–7.9, TC-STSF: mean = 4.1 years, 95% CI = 3.7–4.5, log-
rank p = 0.77, Fig. 4c) or NICM (TC-SF: mean estimated
survival time = 7.6 years, 95% CI = 6.9–8.3, TC-STSF:
mean = 3.2 years, 95%CI = 3–3.4, log-rank p = 0.50, Fig. 4d).
In patients who had undergone VT ablation, there was no
difference in the utilisation of antiarrhythmic medications dur-
ing long-term follow-up (Table 5).
3.5 Redo of TC-SF procedures with TC-STSF
Of the 164 patients in the TC-SF catheter group, 7 patients
subsequently underwent repeat ablation using the TC-STSF
catheter for recurrent VA. Reasons for failure in the index
procedure were adjudicated by 2 senior electrophysiologists.
In two cases, recurrence of VT occurred after endocardial
ablation of NICM requiring an endocardial/epicardial ap-
proach. Difficulties with mapping were identified in three
cases and non-inducibility in one case. Recurrence due to
mid-myocardial location of substrate occurred in one case.
In two cases, the use of CF was considered to aid the success
of the subsequent procedure for VEs mapped to the superior
RV inflow in one and the aorto-mitral continuity in another.
4 Discussion
This study is the largest propensity-matched series assessing the
role of CF in the ablation of VAs to date and the first to
Table 4 Acute success and complications
Normal heart (182) ICM (76) NICM (70)
TC-SF (91) TC-STSF (91) P TC-SF (38) TC-STSF (38) P TC-SF (35) TC-STSF (35) P
Acute success 76 (84) 83 (91) 0.1a 33 (87) 36 (95) 0.2a 25 (71) 22 (63) 0.4a
30-day complications 4 (4) 3 (3) 0.5a 5 (13) 4 (11) 0.6a 2 (6) 4 (11) 0.7a
Tamponade 2 1 1 2 1 2
Stroke 1 0
Heart block 0 1
Death 1 1
Pneumonia 1 0
Pulmonary embolism 1 0
Vascular 1 0 1 0 1 2
Pericarditis 0 1
Coronary dissection 0 1
Values are presented as count (percentage)
ICM ischemic cardiomyopathy, NICM non-ischemic cardiomyopathy, TC-SF Thermocool Surround Flow catheter, TC-STSF Thermocool SmartTouch
Surround Flow catheter
a Chi-square test
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investigate whether measuring CF improves on the outcomes
achieved by entire tip irrigation. The main finding from this
study is that the addition of CF sensing to a 56-hole irrigation
RF ablation catheter was not associated with improved acute
procedural success, complications or long-term outcomes. Prior
studies in sheep models and small human series suggested that
measuring CF improved substrate characterisation and lesion
formation, especially in scar zones [3, 4]. CF achieved in differ-
ent regions of the left ventricle has been found to depend on the
approach used (whether transseptal or transaortic) [5]. The con-
sistent use of both approaches to the left ventricle for patients
with scar-dependent VA at our center might have lessened the
effect of measuring CF. Although the size of our study is
insufficient to make firm conclusions, we postulate that the use
of CF may aid ablation in specific areas within the ventricles.
Areas such as the inflow portion of the right ventricle, the aorto-
mitral continuity, the subaortic vestibule (infero-septal recess),
particularly when the ascending aorta is horizontally situated or
tortuosity of the descending aorta is encountered, may benefit
from the use of CF. In these situations, the manual feedback
afforded to the operator is reduced and often requires significant
catheter torque to manoeuvre the catheter. Optimising catheter-
tissue contact may also be of greater value with deeper
intramyocardial foci. Additionally, CF sensing catheters enable
the operator to visualise the direction of force which may be
advantageous during epicardial ablation. Our propensity-
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Fig. 2 Kaplan-Meier survival analysis of ventricular arrhythmia-free sur-
vival comparing the TC-SF (dotted line) and TC-STSF (solid line) groups
in the whole study population (a), in normal hearts (b), ischemic cardio-
myopathy (c) and non-ischemic cardiomyopathy (d). ICM = ischemic
cardiomyopathy; NICM = non-ischemic cardiomyopathy; TC-SF =
Thermocool Surround Flow; TC-STSF = Thermocool SmartTouch
Surround Flow
J Interv Card Electrophysiol
matched first-time cases included only three epicardial proce-
dures, whichwere insufficient to demonstrate such an advantage.
The failure of CF sensing to offer increased efficacy in our
series may be explained by the fact that there is no clear guid-
ance on how to act on CF values in different ventricular sites of
varying wall thickness. The use of surrogate markers of effec-
tive RF lesion formation, such as initial impedance fall, shown
to be a correlate of good CF [6], and electrical unexcitability of
ablated tissue, may have limited the relative utility of CF sens-
ing. Other variables which influence final lesion formation are
not accounted for by the CF value displayed, such as the dura-
tion of RF energy application, catheter tip angulation as well as
the spatio-temporal variation in contact caused by cardiac and
respiratory motion [7, 8]. These might in the future be
encompassed by a derived, weighted parameter combining
power, time and CF, as recent reports suggest [9]. Due to the
heterogeneity in tissue thickness and composition in both ven-
tricles as well as in diverse cardiac pathologies, region- and
tissue-specific parameters will be required to maximise effec-
tive lesion formation without compromising safety.
Our data shows both the TC-SF and TC-STSF catheters to
be equally safe in treating VAs. This is reassuring as prior
concerns were expressed regarding the safety of the TC-SF
design due to a higher reported frequency of cardiac perfora-
tion as well as atrio-esophageal fistula in left atrial ablation
procedures. This was corroborated by increased steam pops in
canine models and in vitro simulations [10, 11], prompting the
manufacturer to issue a safety notice for the TC-SF catheter in
2014. The safety advantage gained by adding CF sensing to
preexisting platforms may be offset by an increase in catheter
stiffness, as CF-sensing catheters were associated with higher
reported rates of atrio-esophageal fistula as adverse events in
left atrial procedures [12]. This is concordant with our observa-
tion of a higher number of adverse events related to catheter
manipulation with TC-STSF, including cardiac perforation and
coronary injury due to catheter manipulation in the aortic root.
This, although not statistically significant, would warrant cau-
tion while using TC-STSF in more vulnerable locations, e.g.
RVOT and aortic root. CF is monitored by operators during
ablation, but abrupt catheter movements during manipulation
can lead to unanticipated and potentially injurious rises in CF.
Compared with the TC-SF catheter, the use of TC-STSF was
associatedwith reduced fluoroscopy time,mainly in normal heart
VA ablation. A similar observation was noted in a previous com-
parison of both catheters, which mainly comprised atrial ablation
procedures [13]. This may indicate that operator confidence in
catheter tip positioning and contact is less reliant on fluoroscopy
when CF data is available especially in the outflow tracts. An
alternative explanation might be that the TC-STSF cases were
more recent and there has been a steady decline in fluoroscopy
exposure over the past 10 years because of other factors, e.g.
improvement in mapping systems. However, our finding that
fluoroscopy times did not decrease with structural heart disease
in the same epoch would argue against this.
Concordant with our findings, a previous observational
study investigating the utility of CF in VAs using six-hole
irrigation systems failed to show an improvement in procedure
outcome or safety profile [14]. The findings are also analo-
gous to the literature available on CF sensing in atrial ablation
procedures. While non-randomised studies showed lower CF
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Fig. 3 Kaplan-Meier survival analysis of ventricular arrhythmia-free sur-
vival comparing the TC-SF (dotted line) and TC-STSF (solid line) groups
in patients undergoing VE ablation (a) and in patients undergoing VT
ablation (b). TC-SF = Thermocool Surround Flow; TC-STSF =
Thermocool SmartTouch Surround Flow; VE = ventricular ectopics;
VT = ventricular tachycardia
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values to be associated with pulmonary vein reconnection [15,
16], randomised controlled trials failed to demonstrate that the
use of CF improves intermediate to long-term outcome [17].
4.1 Limitations
This was a retrospective single-center study. Specific param-
eter settings were left to operator discretion. However, case-
specific ablation endpoints were the same for both catheters.
The large number of cases and the diversity of etiologies pro-
vide real-world experience of the use of both catheters.
The catheters were used mostly sequentially. Due to the
lack of propensity-matched cases and as only first-time abla-
tions were included, the study comprised a small proportion of
cases using the epicardial approach and no surgical ablation
cases. Image integration with pre-procedure cMRI was not
available; it would have been useful to compare the area of
scar as measured by cMRI and by voltage mapping both with
and without CF data. As the data was collected
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Fig. 4 a, b Kaplan-Meier survival analysis of shock-free survival com-
paring the TC-SF (dotted line) and TC-STSF (solid line) groups in pa-
tients with ischemic cardiomyopathy (a) and with non-ischemic cardio-
myopathy (b). c, d Kaplan-Meier survival analysis of overall survival
comparing the TC-SF (dotted line) and TC-STSF (solid line) groups in
patients with ischemic cardiomyopathy (c) and with non-ischemic cardio-
myopathy (d). ICM = ischemic cardiomyopathy; NICM= non-ischemic
cardiomyopathy; TC-SF = Thermocool Surround Flow; TC-STSF =
Thermocool SmartTouch Surround Flow
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retrospectively, direct comparison between contact force
achieved in the left ventricle with transmitral and transaortic
approach at the same sites in the left ventricle was not
possible.
The modest number of patients undergoing VT ablation
may have been insufficient to find a small potential difference
in outcomes due to the use of contact force in this subset.
5 Conclusion
Both TC-SF and TC-STSF catheters are safe and effective in
treating VA. The addition of CF sensing to a 56-hole open-
irrigation RF catheter did not confer additional benefits in
terms of safety, acute success or long-term outcomes in ablat-
ing VA, but reduced fluoroscopy time in normal heart VA.
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